Petrogenesis of Eocene oceanic basalts from the West Philippine Basin and Oligocene arc volcanics from the Palau-Kyushu Ridge drilled at 20°N, 135°E (Western Pacific Ocean).

The West Philippine Basin (WPB) is a back-arc basin that opened within the Philippine Sea Plate (PSP) between the current position of the Palau-Kyushu Ridge (PKR) and the margin of East Asia. Spreading occurred at the Central Basin Fault (CBF) mainly from 54 until 30 Ma. The PKR was active since ~ 48 to 35 Ma constituting a single volcanic arc with the Izu-Bonin-Mariana (IBM) Arc. At ~ 42 Ma ago spreading rate and direction changed from NE-SW to NS, stopping at ~ 30 Ma. A late phase of spreading and volcanism took place between 30 and 26 Ma. ODP Leg 195 Site 1201 is located in the WPB, ~ 100 km west of the PKR, on 49 Ma crust formed by NE-SW spreading at the CBF. From ~ 35 to 30 Ma, pelagic sedimentation at Site 1201 was followed by turbidite sedimentation, fed mostly by arc-derived volcanic clasts. The geochemical and isotopic features of Site 1201 basement rocks, which represent Eocene WPB oceanic crust, compared with those of Site 1201 volcanics from the turbidite sequence, representing products of the early Mariana Arc (PKR), provide some insights into the early history of the IBM subduction factory. The WPB basement is made up of aphyric to porphyritic basalts with altered olivine, and preserved plagioclase, clinopyroxene and opaques. The PKR volcanics are porphyritic basalts and andesites with plagioclase, clino- and orthopyroxene, hornblende, alkali feldspar and opaques. Variable textures, and degree of alteration suggesting zeolite facies metamorphic grade, characterize both groups of rocks. The mineralogical and geochemical characteristics of the investigated Site 1201 PKR volcanics highlight their calc-alkaline affinity. This feature is at variance with both other PKR rocks, having mostly boninitic and arc tholeiitic affinity, and WPB basement basalt, having tholeiitic affinity, with some characters transitional to arc-like, as expected for a back-arc basin. New Sr and Nd isotope data, coupled with published Sr, Nd, Pb and Hf isotope data (Savov et al., 2006), highlight the Indian Ocean MORB-like character of Site 1201 basement basalts. This suggests that WPB volcanism tapped an upper mantle domain distinct from that underlying the Pacific Plate. The isotopic features of Site 1201 PKR volcanics are more enriched relative to those of basement basalts reflecting higher amounts of subduction-derived component(s) in the source of arc magmas. Th-Nb relationships and isotope geochemistry of the WPB basement and overlaying arc volcanics suggest addition of subducted sediment mostly as siliceous melts, to the mantle source of the arc volcanics. In that respect, Site 1201 PKR volcanics resemble calc-alkaline volcanics of the currently active Mariana Arc. In addition, the calc-alkaline affinity, unradiogenic neodymium, and inferred Middle Oligocene age of PKR volcanics, suggest they might represent an evolved stage of arc volcanism at Palau-Kyushu Ridge, perhaps shortly before the end of its activity

Implications of eocene-age philippine sea and forearc basalts for initiation and early history of the izu-bonin-mariana arc

Whole-rock isotope ratio (Hf, Nd, Pb, Sr) and trace element data for basement rocks at ocean drilling Sites U1438, 1201 and 447 immediately west of the KPR (Kyushu-Palau Ridge) are compared to those of FAB (forearc basalts) previously interpreted to be the initial products of IBM subduction volcanism. West-of-KPR basement basalts (drill sites U1438, 1201, 447) and FAB occupy the same Hf-Nd and Pb-Pb isotopic space and share distinctive source characteristics with εHf mostly >16.5 and up to εHf =19.8, which is more radiogenic than most Indian mid-ocean ridge basalts (MORB). Lead isotopic ratios are depleted, with ²⁰⁶Pb/²⁰⁴Pb = 17.8-18.8 accompanying relatively high ²⁰⁸Pb/²⁰⁴Pb, indicating an Indian-MORB source unlike that of West Philippine Basin plume basalts. Some Sr isotopes show affects of seawater alteration, but samples with ⁸⁷Sr/⁸⁶Sr8.0 appear to preserve magmatic compositions and also indicate a common source for west-of-KPR basement and FAB. Trace element ratios resistant to seawater alteration (La/Yb, Lu/Hf, Zr/Nb, Sm/Nd) in west-of-KPR basement are generally more depleted than normal MORB and so also appear similar to FAB. At Site U1438, only andesite sills intruding sedimentary rocks overlying the basement have subduction-influenced geochemical characteristics (εNd ∼6.6, εHf ∼13.8, La/Yb > 2.5, Nd/Hf ∼9). The key characteristic that unites drill site basement rocks west of KPR and FAB is the nature of their source, which is more depleted in lithophile trace elements than average MORB but with Hf, Nd, and Pb isotope ratios that are common in MORB. The lithophile element-depleted nature of FAB has been linked to initiation of IBM subduction in the Eocene, but Sm-Nd model ages and errorchron relationships in Site U1438 basement indicate that the depleted character of the rocks is a regional characteristic that was produced well prior to the time of subduction initiation and persists today in the source of modern IBM arc volcanic rocks with Sm/Nd>0.34 and εNd ∼9.0

Origin of depleted basalts during subduction initiation and early development of the Izu-Bonin-Mariana island arc: Evidence from IODP expedition 351 site U1438, Amami-Sankaku basin

The Izu-Bonin-Mariana (IBM) island arc formed following initiation of subduction of the Pacific plate beneath the Philippine Sea plate at about 52 Ma. Site U1438 of IODP Expedition 351 was drilled to sample the oceanic basement on which the IBM arc was constructed, to better understand magmatism prior to and during the subduction initiation event. Site U1438 igneous basement Unit 1 (150 m) was drilled beneath 1460 m of primarily volcaniclastic sediments and sedimentary rock. Basement basalts are microcrystalline to fine-grained flows and form several distinct subunits (1a-1f), all relatively mafic (MgO = 6.5–13.8%; Mg# = 52–83), with Cr = 71–506 ppm and Ni = 62–342 ppm. All subunits are depleted in non-fluid mobile incompatible trace elements. Ratios such as Sm/Nd (0.35–0.44), Lu/Hf (0.19–0.37), and Zr/Nb (55–106) reach the highest values found in MORB, while La/Yb (0.31–0.92), La/Sm (0.43–0.91) and Nb/La (0.39–0.59) reach the lowest values. Abundances of fluid-mobile incompatible elements, K, Rb, Cs and U, vary with rock physical properties, indicating control by post-eruptive seawater alteration, but lowest abundances are typical of fresh, highly depleted MORBs. Mantle sources for the different subunits define a trend of progressive incompatible element depletion. Inferred pressures of magma segregation are 0.6–2.1 GPa with temperatures of 1280–1470 °C. New 40Ar/39Ar dates for Site U1438 basalts averaging 48.7 Ma (Ishizuka et al., 2018) are younger that the inferred age of IBM subduction initiation based on the oldest ages (52 Ma) of IBM forearc basalts (FAB) from the eastern margin of the Philippine Sea plate. FAB are hypothesized to be the first magma type erupted as the Pacific plate subsided, followed by boninites, and ultimately typical arc magmas over a period of about 10 Ma. Site U1438 basalts and IBM FABs are similar, but Site U1438 basalts have lower V contents, higher Ti/V and little geochemical evidence for involvement of slab-derived fluids. We hypothesize that the asthenospheric upwelling and extension expected during subduction initiation occurred over a broad expanse of the upper plate, even as hydrous fluids were introduced near the plate edge to produce FABs and boninites. Site U1438 basalts formed by decompression melting during the first 3 Ma of subduction initiation, and were stranded behind the early IBM arc as mantle conditions shifted to flux melting beneath a well-defined volcanic front

The role of the alloy structure in the magnetic behavior of granular systems

The effect of grain size, easy magnetization axis and anisotropy constant distributions in the irreversible magnetic behavior of granular alloys is considered. A simulated granular alloy is used to provide a realistic grain structure for the Monte Carlo simulation of the ZFC-FC curves. The effect of annealing and external field is also studied. The simulation curves are in good agreement with the FC and ZFC magnetization curves measured on melt spun Cu-Co ribbons.Comment: 13 pages, 10 figures, submitted to PR

Basalt derived from highly refractory mantle sources during early Izu-Bonin-Mariana arc development

The magmatic character of early subduction zone and arc development is unlike mature systems. Low-Ti-K tholeiitic basalts and boninites dominate the early Izu-Bonin-Mariana (IBM) system. Basalts recovered from the Amami Sankaku Basin (ASB), underlying and located west of the IBM’s oldest remnant arc, erupted at ~49 Ma. This was 3 million years after subduction inception (51-52 Ma) represented by forearc basalt (FAB), at the tipping point between FAB-boninite and typical arc magmatism. We show ASB basalts are low-Ti-K, aluminous spinel-bearing tholeiites, distinct compared to mid-ocean ridge (MOR), backarc basin, island arc or ocean island basalts. Their upper mantle source was hot, reduced, refractory peridotite, indicating prior melt extraction. ASB basalts transferred rapidly from pressures (~0.7-2 GPa) at the plagioclase-spinel peridotite facies boundary to the surface. Vestiges of a polybaric-polythermal mineralogy are preserved in this basalt, and were not obliterated during persistent recharge-mix-tap-fractionate regimes typical of MOR or mature arcs

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.